| Autor: |
Anne Cossmann, Ulrich Rothbauer, Philipp D. Kaiser, Bjoern Traenkle, Nicole Schneiderhan-Marra, Johanna Marie Griesbaum, Gerhard Lonnemann, Gema Morillas Ramos, Alexandra Dopfer-Jablonka, Matthias Becker, Georg M. N. Behrens, Gérard Krause, Alex Dulovic, Monika Strengert, Karsten Luerken, Eike Wrenger, Metodi V. Stankov, Andrea Beigel, Daniel Junker |
| Rok vydání: |
2021 |
| Předmět: |
|
| DOI: |
10.1101/2021.08.16.21262115 |
| Popis: |
Patients undergoing chronic hemodialysis were among the first to receive SARS-CoV-2 vaccinations due to their increased risk for severe COVID-19 disease and high case fatality rates. To date, there have been minimal longitudinal studies in hemodialysis patients to ascertain whether protection offered by vaccination is long-lasting. To assess how surrogates for protection changed over time, we examined both the humoral and cellular response in a previously reported cohort of at-risk hemodialysis patients and healthy donors, four months after their second dose of Pfizer BNT162b2. Compared to three weeks post-second vaccination, both cellular and humoral responses against the original SARS-CoV-2 isolate as well as variants of concern were significantly reduced, with some dialyzed individuals having no B- or T-cell response. Our data strongly support the need for a third booster in hemodialysis patients and potentially other at-risk individuals. |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
